Dutta Mainak, Subramani Elavarasan, Taunk Khushman, Gajbhiye Akshada, Seal Shubhendu, Pendharkar Namita, Dhali Snigdha, Ray Chaitali Datta, Lodh Indrani, Chakravarty Baidyanath, Dasgupta Swagata, Rapole Srikanth, Chaudhury Koel
School of Medical Science and Technology, Indian Institute of Technology, Kharagpur, West Bengal, India.
Proteomics Lab, National Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, India.
J Proteomics. 2015 Jan 30;114:182-96. doi: 10.1016/j.jprot.2014.10.021. Epub 2014 Nov 8.
Endometriosis is a common benign gynecological disease, characterized by proliferation of functional endometrial glands and stroma outside the uterine cavity. The present study involves investigation of alterations in the serum proteome of endometriosis patients compared to healthy controls using 2DE and 2D-DIGE combined with MALDI TOF/TOF-MS. Comparison of serum proteome of endometriosis patients and healthy subjects revealed 25 significant differentially expressed proteins. Gene ontology and network analysis, performed using PANTHER, DAVID, WebGestalt and STRING, revealed that the differentially expressed proteins are majorly involved in response to stimulus, immune system, metabolic, localization and cellular processes. For serum diagnostic marker identification, several robust statistical screening procedures were applied to identify the set of the most significant proteins responsible for successful diagnosis of different endometriosis stages. Partial least squares (PLS) based marker selection tool and orthogonal partial least squares-discriminant analysis (OPLS-DA) were used to identify the most significant proteins for disease prediction. Western blotting validation in a separate cohort of patients revealed that haptoglobin (HP), Ig kappa chain C region (IGKC), alpha-1B-glycoprotein (A1BG) can be considered effective serum protein markers for the diagnosis of Stage II, III and IV endometriosis. For diagnosis of Stage I, only IGKC and HP seemed promising.
Globally, about 12 in 100 women of reproductive age are diagnosed with endometriosis. The pathogenesis of the disease still remains unclear, leading to non-specific therapeutic approaches for disease management. Moreover, there is a delay of 8-12years in correct diagnosis after the initial onset of symptoms leading to a considerable impact on the woman's lifestyle. Also, the gold standard for diagnosis of endometriosis, laparoscopy, is an invasive procedure. The value of a noninvasive or semi-invasive diagnostic test for endometriosis with easily accessible fluids such as plasma, serum, urine, and saliva is, therefore, rightfully recognized. The present study is expected to considerably improve the understanding of the disease pathogenesis along with improved diagnostics and therapeutic approaches leading to better management of the disease.
子宫内膜异位症是一种常见的良性妇科疾病,其特征是子宫腔外功能性子宫内膜腺体和间质的增殖。本研究采用二维电泳(2DE)和二维差异凝胶电泳(2D-DIGE)结合基质辅助激光解吸电离飞行时间串联质谱(MALDI TOF/TOF-MS),对子宫内膜异位症患者与健康对照者的血清蛋白质组变化进行了研究。子宫内膜异位症患者与健康受试者血清蛋白质组的比较显示有25种显著差异表达的蛋白质。使用PANTHER、DAVID、WebGestalt和STRING进行的基因本体论和网络分析表明,差异表达的蛋白质主要参与对刺激的反应、免疫系统、代谢、定位和细胞过程。为了鉴定血清诊断标志物,应用了几种稳健的统计筛选程序,以确定对不同子宫内膜异位症阶段的成功诊断负责的一组最显著的蛋白质。基于偏最小二乘法(PLS)的标志物选择工具和正交偏最小二乘判别分析(OPLS-DA)用于鉴定疾病预测中最显著的蛋白质。在另一组患者中进行的蛋白质印迹验证表明,触珠蛋白(HP)、免疫球蛋白κ链C区(IGKC)、α-1B-糖蛋白(A1BG)可被视为诊断II、III和IV期子宫内膜异位症的有效血清蛋白标志物。对于I期的诊断,只有IGKC和HP似乎有前景。
在全球范围内,每100名育龄妇女中约有12人被诊断为子宫内膜异位症。该疾病的发病机制仍不清楚,导致疾病管理的治疗方法缺乏特异性。此外,在症状首次出现后8至12年才会做出正确诊断,这对女性的生活方式产生了相当大的影响。而且,子宫内膜异位症诊断的金标准——腹腔镜检查是一种侵入性手术。因此,对于子宫内膜异位症,利用血浆、血清、尿液和唾液等易于获取的液体进行非侵入性或半侵入性诊断测试的价值得到了合理认可。本研究有望大大增进对该疾病发病机制的理解,同时改善诊断和治疗方法,从而更好地管理该疾病。